Growth Strategies Case Study

Sun Pharmaceuticals in 2004

OR

Abstract:
Indian pharmaceutical companies, with their generic drugs have proved their capabilities in the world’s largest and most lucrative markets - the U.S and Europe. These companies with their strong reverse engineering skills have gained a foothold in these key markets. Indian top-tier companies such as Dr. Reddy’s, Ranbaxy, Cipla, Wockhardt and Sun Pharmaceutical Industries Ltd., (SPIL) were the leading players in these markets. SPIL was one of the leading companies in the Indian pharmaceutical industry. It was also the first Indian pharmaceutical company to focus and sell drugs that treated life style segments. It reached a leadership position in each of the therapeutic areas it operated in. The company had used both organic and inorganic growth strategies to grow domestically and internationally.

Pedagogical Objectives:

• To discuss the growth strategies that SPIL adopted to become one of the leading pharmaceutical companies in India
• To understand how SPIL wanted to reposition itself in the post 2005 product patent regime.

Keywords : Sun Pharmaceuticals India Limited; Growth strategies; Dr Reddy's Laboratories Limited; Ranbaxy Laboratories; Indian pharmaceutical industry; Growth Strategies Case Study; Research and development; Generics business; Sun Pharma Advanced Research Center; Mergers and acquisitions; Cipla Limited; United States Food and Drug Administration; United Kingdom Medicines Control Agency; Australia Therapeutic Goods Administration; Caraco Pharmaceutical Laboratories Limited; New chemical entities

Contents : 
Introduction
Background
Sun Pharma: Growth Strategies
Challenges